DOCSLIB.ORG

Wa Mali Malta Alta Ar Datata Taman Utama

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wa Mali Malta Alta Ar Datata Taman Utama WA MALI MALTA USALTA 20170304193A1 AR DATATA TAMAN UTAMA ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017/ 0304193 A1 Soroudi ( 43 ) Pub . Date : Oct. 26 , 2017 ( 54 ) NON - IRRITATING , NON - BLURRING , A61K 31/ 4192 (2006 .01 ) PHOTOSTABLE OPHTHALMIC SUNSCREEN A610 17 /04 ( 2006 . 01 ) COMPOSITION A61K 3330 ( 2006 .01 ) ) U . S . CI. ( 71) Applicant: A . Ebbie Soroudi, Los Angeles , CA CPC . .. A61K 9 / 0048 (2013 .01 ) ; A61Q 17 / 04 (US ) ( 2013 . 01 ) ; A61K 33 / 30 (2013 . 01 ) ; A61K 31 /215 (2013 .01 ) ; A61K 31/ 4192 ( 2013. 01 ) ; (72 ) Inventor: A . Ebbie Soroudi, Los Angeles , CA A61K 31/ 495 ( 2013. 01 ) (US ) (21 ) Appl . No . : 15 /648 , 107 (57 ) ABSTRACT A non - irritation , non - blurring, photostable ophthalmic sun ( 22 ) Filed : Jul. 12, 2017 screen composition contains at least one of the following : bemotrizinol; bisoctrizole ; tris -biphenyl triazine ; and / or Related U . S . Application Data octyl methoxycinnamate . A liquid vehicle base is then a (63 ) Continuation - in - part of application No . 14 /715 , 894 , remainder of the solution by weight. The composition is an filed on May 19 , 2015 . artificial tear formulation or an ophthalmic suspension or ointment. The composition may include at least one inor (60 ) Provisional application No. 62/ 000 , 071, filed on May ganic and /or at least one organic active ingredient . The 19, 2014 , provisional application No . 62 / 361, 189 , inorganic active ingredients may include , but not be limited filed on Jul . 12 , 2016 . to zinc oxide , titanium dioxide , iron oxide , zirconium oxide , and cerium oxide . The organic active ingredients may Publication Classification include, but not be limited to dioxybenzone , octinoxate , (51 ) Int. CI. octisalate , homosalate , avobenzone, octocrylene , para - amin A61K 9 / 00 ( 2006 .01 ) obenzoic acid , cinoxate , methyl anthranilate , octocrylene , A61K 31/ 495 ( 2006 . 01 ) padimate O , ensulizole , sulisobenzone , trolamine salicylate , A6IK 31/ 215 ( 2006 . 01 ) and ecamsule . US 2017 /0304193 A1 Oct. 26 , 2017 NON - IRRITATING , NON - BLURRING , [0008 ]. Accordingly , protecting the ocular structures form PHOTOSTABLE OPHTHALMIC SUNSCREEN UV radiation may be beneficial in preventing such oxidative COMPOSITION damage that leads to all of these very common ophthalmic conditions . Until recently , the only proposed mechanism to CROSS -REFERENCE TO RELATED protect the eyes from UV radiation has been the use of APPLICATIONS glasses with UV protection , sunglasses, and tinted contact lenses . [0001 ] This continuation - in -part patent application claims [0009 ] There is a plethora of prior art suggesting the use priority to application Ser. No . 14 /715 ,894 filed on May 19 , of different physical and /or chemical sunscreen composi 2015 which itself claimed priority to provisional application tions for just the skin and formulations that won ' t damage 62/ 000 ,071 filed on May 19 , 2014 . This continuation - in -part the eye should any formulation get within the eye , but these application also claims priority to provisional application patents and prior art did not envision and / or describe the use 62 /361 , 189 filed on Jul. 12 , 2016 . The entire contents of all of such formulations for protecting the ocular structures in the priority applications (non - provisional and provisional ) any way . For example , Dueva -Koganov et al. ( Pub . No . : US are hereby incorporated in full by these references . 2010 /0226867 A1) proposed a " cosmetic and /or dermato logical” composition that are non - irritating to mammalian DESCRIPTION eyes. While this is a significant advantage for a dermato logical composition not to burn the eyes in case of inadver Field of the Invention tent contact , it does not describe the application of a solution [0002 ] The present invention generally relates to a sun that is designed for “ ophthalmic ” use per se. screen formulation designed for protecting the eyes includ [0010 ] There have been inventions that have proposed ing the conjunctiva , cornea , lens , and retina . More particu formulations specifically for the purpose of protecting the larly , the present invention relates to a non - irritating human eye from UV radiation , but such prior art has sunscreen that is applied directly onto the ocular surface of suggested formulations that are very different than what is the eye for protection from ultraviolet radiation . proposed herein with potential side- effects that may render them impractical for frequent use . Such prior art has pro Background of the Invention posed compositions that would make vision extremely blurry and / or be extremely irritating to the eyes, thus making [0003 ] Ultraviolet radiation is part of the electromagnetic them less suitable for frequent use by the general population . spectrum that reaches the earth from the sun . It has wave [0011 ] For example Michalos ( U . S . Pat. No . 4 ,923 ,693 ) lengths shorter than visible light , making it invisible to the proposed the use of 0 . 3 - 0 . 4 % hydroxypropylmethylcellulose naked eye . These wavelengths are classified as UVA , UVB , in the form of an eyedrop or ointment applied to the eyes or UVC . UVA has the longest of the three at 320 -400 prior to exposure to UV radiation ) . This formulation , while nanometers . UVA is further divided into two wave ranges , effective against UV radiation , would affect vision tremen UVA I, which measures 340 -400 nanometers (nm , or bil dously and make it difficult for the user to see clearly for lionths of a meter ) , and UVA II which extends from 320 -340 hours . nanometers . UVB ranges from 290 to 320 nm . With even [ 0012 ] Baron ( U . S . Pat . No . 5 ,041 , 244 ) described an oph shorter rays , most UVC is fortunately absorbed by the ozone thalmic liquid sunglass that is composed of dosages of layer and does not reach the earth . chromophores in aqueous gel to block transmission of all or [0004 ] Both UVA and UVB penetrate the Earth ' s atmo various spectrums ofUV from the eyes . He has described the sphere and play an important role in conditions such as use of high molecular weight polymers which form viscous premature skin aging , eye damage , hair damage , and certain dispersions and can be used to prolong the curation of the skin cancers . chromophore when the gel is applied to the eye . This alone [0005 ] Photoconjunctivitis and Photokeratitis describe would cause significant blurring of the users ' vision . Further , conditions where ultraviolet radiation inflames and / or dam there is no mention of the irritation that' s caused once this ages the delicate structures of the ocular surface ( the con mixture is directly applied to the eye . This makes Baron ' s junctiva and the cornea , respectively ) . UV exposure to the invention not entirely practical for frequent use by the eyes ( either direct or indirect ) can cause severe redness , public . dryness , irritation , tearing , photosensitivity , and pain . This [0013 ] Smith ( U . S . Publication Number 2013/ 0331362 pain can be so severe as to cause chemosis and sloughing of A1) has described an Ophthalmic Solution For Absorbing the corneal epithelium with resultant scarring and even Ultraviolet Radiation and Method For Absorbing Ultraviolet permanent vision loss . Radiation , where he proposed two active organic ingredients [ 0006 ] Long - term ophthalmic exposure to UV radiation to protect the eyes from UVA and UVB radiation , respec has been associated with permanent thickening of the con tively . This formulation , while effective in theory , would junctiva ( called a pingueculum ) , vascular proliferation and cause significant irritation to the users ' eyes to the point that tissue growth over the cornea ( called a pterygium ), conjunc it would render the formulation unusable due to its severe tival discoloration (melanosis ), even cancer ( e . g . , conjunc side effects . These ingredients , used as described , would also tival/ uveal melanoma) . cause severe blurring of the users ' s vision due to the size of [ 0007 ] Long -standing UV exposure to the eyes has also the molecules proposed . This would also render the Smith been associated with damage to the internal structures of the formulation a poor candidate for regular use . Last, when it eyes , e . g . , the natural lens and the retina . Certain forms of comes to an ophthalmic preparation , the formulation must cataracts ( e . g . , nuclear sclerosis ) , as well as macular degen take into effect the fact that the ingredients used must be eration have been linked to the damage caused by oxidative photostable ( i. e ., that the UV filters don ' t break down or damage from UV exposure . degrade once exposed to UV light) . The Smith patent US 2017 /0304193 A1 Oct. 26 , 2017 proposes the use of avobenzone or octisalate , two of the homosalate, avobenzone , octocrylene , para - aminobenzoic most unstable sunscreen agents . This would further render acid , cinoxate , methyl anthranilate , octocrylene, padimate this formulation ineffective for its proposed use . O , ensulizole , sulisobenzone , trolamine salicylate and ecam [ 0014 ] From another standpoint, it is very important to sule . consider how to dissolve or disperse the proposed ingredi [0021 ] The first portion may comprise 0 . 25 percent to 10 ents in a mixture , which could be utilized as an eye drop / percent by weight. The first portion may comprise 0 . 25 suspension /ointment . The Smith patent publication has not percent to 5 percent by weight. The liquid
Load more

Recommended publications
  • FDA Proposes Sunscreen Regulation Changes February 2019
    FDA Proposes Sunscreen Regulation Changes February 2019 The U.S. Food and Drug Administration (FDA) regulates sunscreens to ensure they meet safety and eectiveness standards. To improve the quality, safety, and eectiveness of sunscreens, FDA issued a proposed rule that describes updated proposed requirements for sunscreens. Given the recognized public health benets of sunscreen use, Americans should continue to use broad spectrum sunscreen with SPF 15 or higher with other sun protective measures as this important rulemaking eort moves forward. Highlights of FDA’s Proposals Sunscreen active ingredient safety and eectiveness Two ingredients (zinc oxide and titanium dioxide) are proposed to be safe and eective for sunscreen use and two (aminobenzoic acid (PABA) and trolamine salicylate) are 1 proposed as not safe and eective for sunscreen use. FDA proposes that it needs more safety information for the remaining 12 sunscreen ingredients (cinoxate, dioxybenzone, ensulizole, homosalate, meradimate, octinoxate, octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, avobenzone). New proposed sun protection factor Sunscreen dosage forms (SPF) and broad spectrum Sunscreen sprays, oils, lotions, creams, gels, butters, pastes, ointments, and sticks are requirements 2 proposed as safe and eective. FDA 3 • Raise the maximum proposed labeled SPF proposes that it needs more data for from SPF 50+ to SPF 60+ sunscreen powders. • Require any sunscreen SPF 15 or higher to be broad spectrum • Require for all broad spectrum products SPF 15 and above, as SPF increases, broad spectrum protection increases New proposed label requirements • Include alphabetical listing of active ingredients on the front panel • Require sunscreens with SPF below 15 to include “See Skin Cancer/Skin Aging alert” on the front panel 4 • Require font and placement changes to ensure SPF, broad spectrum, and water resistance statements stand out Sunscreen-insect repellent combination 5 products proposed not safe and eective www.fda.gov.
    [Show full text]
  • Chemical UVR Absorbers
    Chemical UVR Absorbers The names given in bold and used Diisopropyl methyl cinnamate Glyceryl ethyihexanoate dimethoxy- throughout this handbook are those of Empirical formula: cinnamate the International Nomenclature of C 6H22O2 Chemical names. Cosmetic Ingredients. Glyceryl octanoate dimethoxycinnamate; Chemical names: 2-propenoic acid, 3-(4-methoxyphenyl)-, 2-Propenoic acid, 3-12,4bis(1 diester with 1 ,3-dihydroxy-2-(2-ethyl-1 - methylethyphenyl-methyl ester; 2,5- oxohexyl)oxypropane diisopropyl methyl cinnamate _ lsoamyl-para-methoxycinnamate Ethyihexyl methoxycinnamate Empirical formula: Empirical formula: C151-12003 C 8H26O3 Chemical names: Cinnamates Chemical names: Amyl4-methoxycinnamate; isopentyl-4- 2-Ethylhexyl-4-methoxycin nam ate; methoxycinnamate; isopenlyl-para- Cinoxate 2-ethyl-hexyl-para-methoxycinnamate; methoxy-cinnamate; 3-(4-methoxyphenyl)- Empirical formula: para-methoxycinnamic acid, 2-ethylhexyl 2-propenoic acid, isopentyl ester Ci4HieO4 ester; 3-(4-methoxyphenyl)-2-propenoic acid, 2-ethylhexyl ester; octinoxate; octyl Trade names: Chemical names: methoxycinnamate; 2-propenoic acid, 3- Neo Heliopan type E 1000; Solarum AMC 2- Ethoxyothyl-para-methoxyci n nam ate; (4-methoxyphenyl)-2-ethylhexyl ester 2-propenoic acid, 3-(4-methoxyphery- para-A minobenzoic acids (PA BAs) 2-ethoxyethyl ester; 2-ethoxyethyl-4- Trade names: methoxycinnamate AEC Octyl Methoxycinnamate; Escalol Amyl dimethyl FABA 557; Eusolex 2292; Heliosol 3; Empirical formula: Trade names: Jeescreen OMC; Katoscreen OMC; Nec C14H21 NO2 Giv Tan F; Phiasol
    [Show full text]
  • WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 8/30 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/054376 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 September 2012 (10.09.2012) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/532,701 9 September 201 1 (09.09.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): UNIVER¬ kind of regional protection available): ARIPO (BW, GH, SITY OF FLORIDA RESEARCH FOUNDATION, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, INC.
    [Show full text]
  • Sun Protection
    [ Oncology Watch] Sun Protection: What We and Our Patients Need to Know To preserve their health and the appearance of their skin, patients need straight- forward, practical advice on susncreen selection and protection strategies. By Jonathan Wolfe, MD rom preventing skin cancer to pre- measures protection against cutaneous burning. Even a FDA public education serving a youthful appearance, burning—the effects of UVB—and does piece states, “A higher number means it Fsunscreens play an important role not account for UVA radiation at all.5 As protects longer.”7 This is not a strictly in dermatologic care. However, some a result, a product with a high SPF could accurate interpretation of the SPF value confusion persists among patients and actually confer little or no protection and ignores the fact that unique proper- even some practitioners when it comes to against UVA. ties of the main sunscreen ingredients SPF, available chemical and physical sun- The somewhat esoteric description of (chemical or physical) and the formula- screens, and the best advice for sun SPF calculation is available online at the tion (waterproof, water resistant) influ- avoidance. In recognition of the AAD’s FDA website.6 Ultimately, the SPF num- ence duration of protection. Skin Cancer Detection and Prevention ber represents the ratio of the MED for Patients also often falsely assume that Month, I’ll review important patient protected skin (MED(PS)) to the MED the increase in SPF value is proportion- education points. for unprotected skin (MED(US)). Tests ate to the increase in UVB protection. It are conducted only in patients with skin is not.
    [Show full text]
  • Sun Protection
    DRUG NEWS Recommending the Best Sun Protection Clinical Pearls: o Recommend a “broad-spectrum” sunscreen – one that covers UVB, UVA1, and UVA2. o Recommend SPF 30-50 o Advise on non-pharmacological sun protection methods o Emphasize proper sunscreen application technique o Emphasize skin protection when taking drugs known to cause photosensitivity. Familiarize yourself with known implicated drugs by referring to appendix 2. Background 1-4 The sun emits 3 types of ultraviolet (UV) radiation: UVC (100-290 nm), UVB (290-320 nm), and UVA (320 -400 nm). UVA rays can be further divided into the shorter UVA2 rays and the longer UVA1 rays. UVC rays, the shortest rays, are completely absorbed by the ozone layer, whereas UVB rays penetrate the epidermis and UVA rays, the longest rays, penetrate into the dermis. The main consequence of UVB irradiation is sunburn, but can also include immunosuppression and skin cancer. Consequences of UVA radiation include: phototoxicity (i.e. involvement in drug-induced sun sensitivity reactions), photo-aging, immunosuppression, and skin cancer. What is SPF? 2,5,6,7 It is easy to be misled by Sun Protection Factors (SPF). SPF is assessed through a standardized test by finding the ratio of the minimal dose of solar radiation that produces perceptible erythema (i.e., minimal erythema dose) on sunscreen-protected skin compared with unprotected skin. Sunburn is caused primarily by UVB rays (and shorter UVA2 rays), and thus SPF indicates mostly UVB protection. However, UVA protection is equally important since it is responsible for photo-aging and cancer. Therefore, it is important to look for the phrase “broad spectrum” when choosing a sunscreen as broad spectrum indicates both UVB and UVA protection.
    [Show full text]
  • Food and Drug Administration, HHS § 352.20
    Food and Drug Administration, HHS § 352.20 (c) Cinoxate up to 3 percent. than 2 to the finished product. The fin- (d) [Reserved] ished product must have a minimum (e) Dioxybenzone up to 3 percent. SPF of not less than the number of (f) Homosalate up to 15 percent. sunscreen active ingredients used in (g) [Reserved] the combination multiplied by 2. (h) Menthyl anthranilate up to 5 per- (2) Two or more sunscreen active in- cent. gredients identified in § 352.10(b), (c), (i) Octocrylene up to 10 percent. (e), (f), (i) through (l), (o), and (q) may (j) Octyl methoxycinnamate up to 7.5 be combined with each other in a single percent. product when used in the concentra- (k) Octyl salicylate up to 5 percent. tions established for each ingredient in (l) Oxybenzone up to 6 percent. § 352.10. The concentration of each ac- (m) Padimate O up to 8 percent. tive ingredient must be sufficient to (n) Phenylbenzimidazole sulfonic contribute a minimum SPF of not less acid up to 4 percent. than 2 to the finished product. The fin- (o) Sulisobenzone up to 10 percent. ished product must have a minimum (p) Titanium dioxide up to 25 percent. SPF of not less than the number of (q) Trolamine salicylate up to 12 per- sunscreen active ingredients used in cent. the combination multiplied by 2. (r) Zinc oxide up to 25 percent. (b) Combinations of sunscreen and skin [64 FR 27687, May 21, 1999] protectant active ingredients. Any single sunscreen active ingredient or any per- EFFECTIVE DATE NOTE: At 67 FR 41823, June mitted combination of sunscreen ac- 20, 2002, § 352.10 was amended by revising tive ingredients when used in the con- paragraphs (f) through (n), effective Sept.
    [Show full text]
  • Four Common Sunscreen Questions – Spring 2015
    Four common sunscreen questions – Spring 2015 Use this information SPF to help you advise 30 your customers about Use the Sun Protection System sunscreen use. 30 SP F 1. How do sunscreens filter the slip, slop, slap, and wrap sun’s rays? Sunscreens may contain physical or chemical Ethoxyethyl p-methoxycinnamate barriers to screen skin against the sun’s (cinoxate)) ultraviolet radiation (UV radiation). While physical barriers reflect or scatter the UV rays, » Salicylates (Homomenthyl salicylate chemical barriers act by absorbing the UV (homosalate), Ethylhexyl salicylate (octyl radiation before it hits the skin. salicylate/octisalate), Trolamine salicylate General advice is to choose a sunscreen which » Avobenzone (butyl methoxydibenzoylmethane) is broad spectrum, which means it filters both UVA and UVB rays. Those who have sensitive » Ecamsule ((terephthalylidene dicamphor skin should choose a sunscreen labelled sulfonic acid; Mexoryl SX) hypoallergenic or low irritant. » Ensulizole ((phenylbenzimidazole sulfonic Typical chemical absorbers include: acid) » Aminobenzoic acid derivatives (Glyceryl » Bemotrizinol (Tinosorb S) PABA), Padimate O, Roxadimate) » Bisoctrizole (Tinosorb M) » (Dioxybenzone, Benzophenones Physical blockers are titanium dioxide and Oxybenzone, Sulisonbenzone) zinc oxide. When applied they leave a thick » Cinnamates (Octocrylene, Octyl opaque (white) layer on the skin. Microfine or methoxycinnamate (octinoxate), nanoparticles of both are transparent on the skin and reflect UV radiation. 2. Do babies’ need a special sunscreen? » Babies’ skin is very sensitive and can sunburn easily so keep them out of the sun. » Once a baby is moving use the sun protection system. » Patch test an untried sunscreen on the skin 24 hours before applying it widely to check that there is no reaction.
    [Show full text]
  • Foolproof Tips for Staying Safe in The
    Summer Sun eFoolproofssentials Tips for Staying Safe in the Sun Happy summer! It’s finally summer! That means cookouts, beach vacations, and relaxing by the pool. Not many people will argue that there’s a better way to celebrate the summer season than by spending more time outdoors and enjoying some sunshine. However, with the summer season comes some responsibility to take care of yourself – especially your skin. Too much time in the sun can lead to wrinkles, premature aging, and even skin cancer. While sunburns might not seem like a big deal, they can do a lot of damage in a short amount of time. On average, about half of the U.S. population experiences a sunburn at least once a year. This means that many Americans aren’t practicing essential sun safety rules. Skin cancer is the most common form of cancer in the United States. It’s estimated that nearly 9,500 people in the U.S. are diagnosed with it every day, according to the American Academy of Dermatology. And according to the Skin Cancer Foundation, one in five Americans will develop skin cancer by the age of 70. These statistics show that many Americans aren’t doing enough to protect their skin and their overall health. We created this sun safety guide to educate you about the importance of sun protection, as well as share some tips on how to have a safe summer. In this guide you’ll learn: • Best practices for sun safety • How to choose the best sunscreen • Common risk factors for skin cancer • Tips for skin cancer prevention Plus, we also included a printable tip sheet for employers to pass around the office to help educate their employees on the importance of sun safety.
    [Show full text]
  • Sunscreen: the Burning Facts
    United States Air and Radiation EPA 430-F-06-013 Environmental Protection (6205J) September 2006 1EPA Agency Sun The Burning Facts Although the sun is necessary for life, too much sun exposure can lead to adverse health effects, including skin cancer. More than 1 million people in the United States are diagnosed with skin cancer each year, making it the most common form of cancer in the country, but screen: it is largely preventable through a broad sun protection program. It is estimated that 90 percent of non- melanoma skin cancers and 65 percent of melanoma skin cancers are associated with exposure to ultraviolet 1 (UV) radiation from the sun. By themselves, sunscreens might not be effective in pro­ tecting you from the most dangerous forms of skin can- cer. However, sunscreen use is an important part of your sun protection program. Used properly, certain sun­ screens help protect human skin from some of the sun’s damaging UV radiation. But according to recent surveys, most people are confused about the proper use and 2 effectiveness of sunscreens. The purpose of this fact sheet is to educate you about sunscreens and other important sun protection measures so that you can pro­ tect yourself from the sun’s damaging rays. 2Recycled/Recyclable—Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper How Does UV Radiation Affect My Skin? What Are the Risks? UVradiation, a known carcinogen, can have a number of harmful effects on the skin. The two types of UV radiation that can affect the skin—UVA and UVB—have both been linked to skin cancer and a weakening of the immune system.
    [Show full text]
  • Almost Summer Sun Protection Edition: Sunscreen 2019, Sunscreen Danger?, UPF Clothing
    © Take 3 – Practical Practice Pointers June 3, 2019 Edition Almost Summer Sun Protection Edition: Sunscreen 2019, Sunscreen Danger?, UPF Clothing From the Consumer Reports and Caveat Emptor 2019 1) Sunscreen 2019: Not All Sunscreens Deliver Claimed SPF Ultraviolet radiation (UV) exposure is recognized as a major environmental risk factor for both melanoma and keratinocyte cancers. The sun protection factor (SPF) is a relative measure of how long a sunscreen will protect you from UVB rays, which are the chief cause of sunburn and a contributor to skin cancer. Usually the number is explained as the amount of time it takes an individual’s skin to burn when it’s covered in sunscreen compared with when it’s not. For example, assuming you apply—and reapply—the sunscreen correctly, if you’d normally burn after 20 minutes in the sun an SPF 30 protects for about 10 hours. SPF calculations do not apply to UVA rays, which can tan and age skin and also trigger skin cancer. Thus the need for a broad-spectrum sunscreen that provides protection against both types of UV rays. However, no sunscreen blocks 100 percent of UVA or UVB rays. The breakdown: SPF 30 blocks 97 percent of UVB rays, SPF 50 blocks 98 percent, and SPF 100 blocks 99 percent. The Consumer Reports organization yearly tests sunscreens to see how close they approximate their claims. In 2019, of the 82 lotions, sprays, sticks, and lip balms tested, 32 tested at less than half their labeled SPF number. These results aren’t a fluke. Similar patterns have been found in previous years’ sunscreen tests.
    [Show full text]
  • Federal Register/Vol. 84, No. 38/Tuesday, February 26, 2019
    6204 Federal Register / Vol. 84, No. 38 / Tuesday, February 26, 2019 / Proposed Rules DEPARTMENT OF HEALTH AND the public. Similarly, if your submission 1978–N–0018 (formerly Docket No. HUMAN SERVICES includes safety and effectiveness data or FDA–1978–N–0038) for ‘‘Sunscreen information marked as confidential by a Drug Products for Over-the-Counter Food and Drug Administration third party (such as a contract research Human Use.’’ Received comments, those organization or consultant), you should filed in a timely manner (see 21 CFR Parts 201, 310, 347, and 352 either include a statement that you are ADDRESSES), will be placed in the docket [Docket No. FDA–1978–N–0018] (Formerly authorized to make the information and, except for those submitted as Docket No. FDA–1978–N–0038) publicly available or include an ‘‘Confidential Submissions,’’ publicly authorization from the third party viewable at https://www.regulations.gov RIN 0910–AF43 permitting the information to be or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday Sunscreen Drug Products for Over-the- publicly disclosed. If you submit data through Friday. Counter Human Use without confidential markings in response to this document and such • Confidential Submissions—To AGENCY: Food and Drug Administration, data includes studies or other submit a comment with confidential HHS. information that were previously information that you do not wish to be made publicly available, submit your ACTION: Proposed rule. submitted confidentially (e.g., as part of a new drug application), FDA intends to comments only as a written/paper SUMMARY: The Food and Drug presume that you intend to make such submission.
    [Show full text]
  • A Guide to United States Cosmetic Products Compliance Requirements
    NISTIR 8178 A Guide to United States Cosmetic Products Compliance Requirements NISTIR 8178 A Guide to United States Cosmetic Products Compliance Requirements Lisa Benson Karen Reczek This publication is available free of charge from: https://doi.org/10.6028/NIST.IR.8178 NISTIR 8178 A Guide to United States Cosmetic Products Compliance Requirements Lisa M. Benson* Karen Reczek Standards Coordination Office * Dakota Consulting This publication is available free of charge from: https://doi.org/10.6028/NIST.IR.8178 May 2017 Includes updates as of May 31, 2017; see Appendix A U.S. Department of Commerce Wilbur L. Ross, Jr., Secretary National Institute of Standards and Technology Kent Rochford, Acting NIST Director and Under Secretary of Commerce for Standards and Technology Acknowledgements The lead authors for this document Karen Reczek, NIST, and Lisa M. Benson, Dakota Consulting, under contract to the Standards Coordination Office of NIST. Additional guidance, initial research, and review of the document were provided by the staff of the Standards Coordination Office of NIST including: Mary Donaldson and Erik Puskar. Invaluable support was also received from the knowledgeable experts of the Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food and Drug Administration (FDA), Federal Trade Commission (FTC), International Cosmetics Manufacturers and Distributors Association (ICMAD), International Trade Administration (ITA), the Personal Care Products Council (PCPC), This publication is available free of charge from: ht and UL, Inc. who provided input into the document and conducted a thorough review. From the CPSC: Mary Boyle, Patricia Pollitzer, and Mary Toro; From the EPA: Keith Mason and Alexander Metcalf; From the FDA: Jeffrey Read, Linda Katz, and Tracy DuVernoy; From the FTC: Stephen C.
    [Show full text]